01Biogen will report Q3 2026 earnings on October 28 after market close with expected EPS of $2.00 versus $0.00 last year.
02Revenue is projected at $2.6 billion, representing year-over-year growth from the prior year quarter.
03The stock trades at $252.91 with a $25.3 billion market capitalization as of the article date.
04Biogen has beaten analyst estimates in the past three quarters, with Q2 2026 showing a 53.2% EPS surprise.
05Investors should evaluate revenue growth, margin trends, and forward guidance alongside the headline EPS number.
Earnings Results
Biogen Inc. (NASDAQ:BIIB) is scheduled to report its Q3 earnings results on October 28, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $2.00, above the $0.00 reported in the same quarter last year. Revenue is expected to come in at $2.6B, up from a year ago.
Company Overview
The stock currently trades at $252.91 with a market capitalization of $25.3B.
Ahead of Biogen Inc.'s earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Biogen Inc. should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.